H. Lundbeck A/S

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines

Other Names/Subsidiaries

  • Abide Therapeutics
  • Alder Biopharmaceuticals
  • Chelsea Therapeutics International
  • Longboard Pharmaceuticals
  • Lundbeck La Jolla Research Center
  • Lundbeck Seattle Biopharmaceuticals
  • Ovation Pharmaceuticals
  • Saegis Pharmaceuticals
See more in Biomedtracker

Latest on H. Lundbeck A/S

Scrip

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Lundbeck’s transformation under CEO Charl van Zyl continues apace and the CNS-focused Danish drugmaker has raised its full-year guidance after posting a strong set of financials for the first quarter.

In Vivo

How Charl Van Zyl Is Reimagining Lundbeck

 
• By David Wild

Amid an industry-wide scramble to secure growth beyond looming patent cliffs, Denmark’s Lundbeck is undergoing a strategic transformation under CEO Charl van Zyl. Since taking the helm in 2023, van Zy

In Vivo

Dealmaking Quarterly Statistics, Q4 2024

 
• By Maureen Riordan and Deanna Kamienski

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

In Vivo

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By Ed Silverman

As the pharmaceutical industry invests more money than ever before to develop new weight loss treatments, a growing number of patient advocates and academics say companies have, ironically, failed to